You have a $250 gift voucher waiting for you

[Holly Porter]

Last month's picks
 
 
 
 
Eyemakers, Inc.
PK: EYEM
 
***Estimated target
 
07 pp/s 2 months
12 pp/s 3 months
 
Current volume average
Approx 2.3 mill per day
QUICK FACTS
Ticker Symbol: EYEM 
Sector: Medical 
Industry: Specialty Medical Services

MARKET STATS: EYEM
Share Price
$.013

Shares Outstanding
65,000,000*

Market Capitalization
942,500**

52 Week High
$.2

52 Week Low
$.01

*as of 2003-10-04
**as of 2004-01-23

 
  

COMPANY DESCRIPTION

Eyemakers, Inc. is a company in transformation. From its origins as a practice 
management provider to the optometric field, the Company has since become into 
a provider of corrective eye surgery as well as cataract and glaucoma treatment 
and surgery. With a just announced acquisition, the Company is now poised to 
become an aggressive participant in the kidney dialysis arena. Eyemakers feels 
it can fill an unexploited niche in the healthcare field, namely focusing on 
specialized care such as kidney dialysis, dental and eye specialties in 
dedicated facilities in the United States and abroad

 

Important Developments


Announced the signing of a letter of interest to acquire a company that 
provides LASIK corrective surgery to its patients in the western U.S. This 
company had revenues of $1.3 MM in 2002 and is on track with projected 2003 
revenues of over $2 MM. The two companies are now in the process of finalizing 
the share purchase agreement and the transaction is expected to close in the 
first quarter of 2004


Previously announced payment of $185,000 to acquire 2 European eye clinics and 
mobile surgery business, this has been converted into equity and an agreement 
has been reached to acquire the balance of the company in the first quarter of 
2004. The Company is planning to use a debt instrument (interest and principle 
payable semi-annually) to complete this transaction. Revenues for this 
acquisition were $3.8 MM in 2002 and are expected to be $6.0 MM in 2003. These 
increased revenues will be accomplished through expansion and better 
utilization of existing facilities, as well as adding dental and dialysis 
services.


Previously announce acquisition of a kidney dialysis has been closed and 
operation is expected to commence in the first quarter of 2004. The kidney 
center will run at the annual rate of $1.5 M fro the start, since this is a 
government contract with a minimum guaranteed number of patients. Plans are to 
open 2 additional dialysis clinics in calendar year 2004 with estimated 
revenues of $3.0 MM.


Clinic management. The company is in discussions to manage the eye surgery, 
dental and dialysis specialties in a large urban hospital. It is anticipated 
that this will be one of a number of such agreements the Company will make in 
the coming year.



 
RECENT NEWS AND EVENTS
1 12/17/03 Eyemakers Enters into Final Negotiations to Purchase Two European 
Eye Clinics 
2 12/15/03 Interview With Ernest Remo, CEO of Eyemakers, Is Featured at 
SmallCapVoice.com 
3 12/15/03 Eyemakers Announces Completion of Acquisition of Dialysis Center 
4 10/28/03 Eyemakers, Inc. Announces Acquisition Of Dialysis Center 
5 10/14/03 Eyemakers Announces Agreement On Final Terms For Proposed 
Acquisitions 
6 9/18/03 Eyemakers Announces New Name for Company 
 





This release may contain statements that constitute forward-looking statements 
within the meaning of Section 27A of the Securities Act of 1933, as amended, 
and Section 21E the Securities Exchange Act of 1934, as amended. The words 
"may," "would," "will," "expect," "estimate," "anticipate," "believe," 
"intend," "estimated target," and similar expressions and variations thereof 
are intended to identify forward-looking statements. Investors are cautioned 
that any such forward-looking statements are not guarantees of future 
performance and involve risks and uncertainties, many of which are beyond the 
Company's ability to control, and that actual results may differ materially 
from those projected in the forward-looking statements as a result of various 
factors. It is strongly recommended that any purchase or sale decision be 
discussed with a financial adviser, or a broker-dealer, or a member of any 
financial regulatory bodies. The information contained in this profile is 
provided as an information service only. The accuracy or completeness of the 
information is not warranted and is only as reliable as the sources from which 
it was obtained. Investors are cautioned that they may lose all or a portion of 
their investment if they make a purchase in the profiled stocks. There has been 
no compensation given for this email.